Halozyme has collaboration agreements for our proprietary ENHANZE® technology with Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb and Alexion. These partnerships help to fund the company through the receipt of licensing fees, developmental and commercial milestone payments, and royalty payments upon commercialization.

We also seek non-clinical and clinical collaborations for our lead oncology asset, PEGPH20 (pegvorhyaluronidase alfa), to study its pan-tumor potential. Currently, Halozyme is partnered with Eisai to study PEGPH20 in patients with breast cancer and with Genentech to study PEGPH20 in patients with gall bladder cancer, cholangiocarcinoma, pancreatic cancer, gastric cancer and up to four additional tumor types.

For more information on partnering with Halozyme, please contact a member of the Business Development Team.



You are now leaving Halozyme.com. Halozyme is not responsible for or endorses the content of the linked site.